| 1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
| 12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
| 12/14/2005 | CV | Market Commentary: Intel, Ceradyne trade higher; United Dominion re-offered; Entergy up in gray; OSI launches $100 million
|
| 11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
| 8/15/2005 | CV | Market Commentary: Agilent issue gains to par on call; Fleetwood in for bumpy ride; Calpine issues up despite warning
|
| 8/1/2005 | CV | Market Commentary: CommScope jumps, but Isolagen tumbles amid slightly weaker convertibles market
|
| 12/22/2004 | CV | Abgenix greenshoe exercised, raising convertibles to $300 million
|
| 12/17/2004 | CV | Market Commentary: IVAX reoffered at 98.5; BearingPoint up to 101.25; Charter up on M&A talk; PSEG soars on buyout buzz
|
| 12/16/2004 | CV | New Issue: Abgenix sells upsized $225 million convertible to yield 1.75%, up 30%
|
| 12/16/2004 | CV | Market Commentary: Abgenix goes to 104; NRG climbs to 106.5; Gateway, BearingPoint up when-issued
|
| 12/15/2004 | CV | Market Commentary: Abgenix bid at 102.5 in gray market; NRG goes to 105; Gateway, Dover, BearingPoint rush market
|
| 12/14/2004 | CV | Abgenix $150 million convertible talked to yield 1.75%-2.25%, up 25%-30%
|
| 12/14/2004 | CV | Market Commentary: NRG trades up 3.5 points in gray market, terms tightened; Abgenix launches new deal
|
| 12/14/2004 | CV | Abgenix to retire some 2007 convertibles with $150 million convertible sale proceeds
|
| 4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
| 4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
| 11/10/2003 | CV | Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
| 9/4/2002 | CV | Market Commentary: Market tone improves but still patchy; Symantec, Calpine gain
|
| 7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
| 7/8/2002 | CV | Market Commentary: Market idled by stock slump, summer, lack of new issues
|
| 6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
| 5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
| 5/14/2002 | CV | Market Commentary: Broadbased gains as better retail sales confirm recovery signs
|
| 4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
| 3/4/2002 | CV | Market Commentary: Convertibles buyers chase paper higher; new GM deal up sharply
|
| 3/1/2002 | CV | Market Commentary: Convertibles bounce but new paper lags
|
| 2/28/2002 | CV | Market Commentary: Convertibles choppy, lower but GM deal upped to $3.25 billion
|
| 2/27/2002 | CV | New Issue: Abgenix $200 million convertibles yield 3.5%, up 15%
|
| 2/27/2002 | CV | Market Commentary: Convertibles mixed, new deals at center stage
|
| 2/26/2002 | CV | Abgenix $200 million convertibles talked at 3.25-3.75% yield, up 15-20%
|
| 2/26/2002 | CV | Market Commentary: Convertibles mixed, players welcome slew of new deals
|
